Sri Indu Drugs India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 70.44%
(FY 2023)
- Profit 532.54%
(FY 2023)
- Ebitda 60.11%
(FY 2023)
- Net Worth 421.99%
(FY 2023)
- Total Assets 59.73%
(FY 2023)
About Sri Indu Drugs India
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rahul Tammineedi, Indu Govina, and Govina Ramakrishna serve as directors at the Company.
- CIN/LLPIN
U24232TG2009PTC064701
- Company No.
064701
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Aug 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Sri Indu Drugs India Private Limited offer?
Sri Indu Drugs India Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Inorganic Salts, Water Coagulant, Poly Aluminium Chloride.
Who are the key members and board of directors at Sri Indu Drugs India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rahul Tammineedi | Additional Director | 29-Aug-2022 | Current |
Indu Govina  | Director | 10-Aug-2009 | Current |
| Govina Ramakrishna | Director | 10-Aug-2009 | Current |
Financial Performance of Sri Indu Drugs India.
Sri Indu Drugs India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 70.44% increase. The company also saw a substantial improvement in profitability, with a 532.54% increase in profit. The company's net worth Soared by an impressive increase of 421.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Indu Drugs India?
In 2023, Sri Indu Drugs India had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sri Indu Drugs India?
Unlock and access historical data on people associated with Sri Indu Drugs India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Indu Drugs India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Indu Drugs India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.